Xena, I was citing frrol's quotes in his reply to your post.
To my earlier comment "pooled data shows nothing," it's more in the context of us retail guys on the scent of a gamechanger. I'm sure any decline in pooled Part B data post 31wk, will still beat DPZ decline. This is a safety/dose optimization/long-term tolerability study. So this statistical contortion may be for P2/3 design. I'm ready to take my lumps over the remainder Part B press releases but in my mind we have a new game, once P2/3 trial design is made public. I feel pretty good A 2-73 works (with Hampel et. al. comments in mind.)
Last point to note - in alluding to collaborative efforts, it seems like Missling has moved on from usage of the word "partnership" to "inlicensing"
News 
Market Data 
Discover 
